key: cord-0865905-tgndqsa0
authors: Mankelow, Tosti J.; Singleton, Belinda K.; Moura, Pedro L.; Stevens‐Hernandez, Christian J.; Cogan, Nicola M.; Gyorffy, Gyongyver; Kupzig, Sabine; Nichols, Luned; Asby, Claire; Pooley, Jennifer; Ruffino, Gabriella; Hosseini, Faroakh; Moghaddas, Fiona; Attwood, Marie; Noel, Alan; Cooper, Alex; Arnold, David T.; Hamilton, Fergus; Hyams, Catherine; Finn, Adam; Toye, Ashley M.; Anstee, David J.
title: Blood group type A secretors are associated with a higher risk of COVID‐19 cardiovascular disease complications
date: 2021-04-02
journal: EJHaem
DOI: 10.1002/jha2.180
sha: 46d06f81b7cb246e3e399e8eba40216eec3d1876
doc_id: 865905
cord_uid: tgndqsa0

The SARS‐CoV‐2 virus causes COVID‐19, an infection capable of causing severe disease and death but which can also be asymptomatic or oligosymptomatic. We investigated whether ABO blood group or secretor status was associated with COVID‐19 severity. We investigated secretor status because expression of ABO glycans on secreted proteins and non‐erythroid cells are controlled by a fucosyltransferase (FUT2), and inactivating FUT2 mutations result in a non‐secretor phenotype which protects against some viral infections. Data combined from healthcare records and our own laboratory tests (n = 275) of hospitalized SARS‐CoV‐2 polymerase chain reaction positive patients confirmed higher than expected numbers of blood group A individuals compared to O (RR = 1.24, CI 95% [1.05, 1.47], p = 0.0111). There was also a significant association between group A and COVID‐19‐related cardiovascular complications (RR = 2.56, CI 95% [1.43, 4.55], p = 0.0011) which is independent of gender. Molecular analysis revealed that group A non‐secretors are significantly less likely to be hospitalized than secretors. Testing of convalescent plasma donors, among whom the majority displayed COVID‐19 symptoms and only a small minority required hospitalization, group A non‐secretors were slightly over‐represented. Our findings showed that group A non‐secretors are not resistant to infection by SARS‐CoV‐2, but are more likely to experience a less severe form of associated disease.

Molecular analysis revealed that group A non-secretors are significantly less likely to be hospitalized than secretors. Testing of convalescent plasma donors, among whom the majority displayed COVID-19 symptoms and only a small minority required hospitalization, group A non-secretors were slightly over-represented. Our findings showed that group A non-secretors are not resistant to infection by SARS-CoV-2, but are more likely to experience a less severe form of associated disease.

Genetic diversity among members of animal species including Homo sapiens is essential for their survival in response to newly emergent and evolving pathogens [1] . Human blood group antigens are among the first polymorphic structures encountered by viruses and bacteria upon airborne contact with respiratory, gastrointestinal and urinogenital mucosal surfaces [2] . The carbohydrate antigens of the ABO and Lewis blood group systems are found on mucosal surfaces where their presence is controlled by a fucosyltransferase (FUT2) [3, 4] . In the presence of active FUT2 A, B, H, and Le b antigens can be expressed on mucosal surfaces. Individuals with this phenotype are known as secretors [5, 6] . In individuals lacking active FUT2, known as non-secretors, only the Le a antigen can be expressed [5] . There are several well studied interactions between host cells and both bacteria (Helicobacter pylori, Vibrio cholera) and viruses (noroviruses, rotaviruses) which are known to depend on the presence of these antigens [7, 8] . In particular, it is clearly established that common strains of norovirus and rotavirus fail to infect non-secretors [9] [10] [11] [12] .

A novel coronavirus (severe acute respiratory syndrome coron- [13] . Currently, more than 112 million people have been infected worldwide, and, of those, more than 2.5 million have died as a result of the disease. It was apparent from the earliest studies that disease severity in individual patients varied considerably, ranging from asymptomatic infection to fatal illness [14] . Zhao et al provided the first evidence of an association between blood group polymorphisms and with disease severity [15] . In a study of over 2000 infected patients from Wuhan, China, it was noted that group A phenotype was found more frequently than expected in patients with COVID-19, whereas group O occurred less commonly than expected in the general population, suggesting that group A individuals are at greater risk from COVID-19 than those of group O. This observation led us to undertake a study of the association of blood group polymorphisms (ABO and secretor status) with COVID-19 severity in hospitalized patients in Bristol, UK.

Here we report a significantly increased frequency of hospitalization for blood group A compared to blood group O patients with COVID-19. This was accompanied by a significantly higher rate of respiratory failure at admission but had no significant association with length of stay or patient death rate. Importantly, we observe a trend between blood group A and cardiovascular complications, which we confirm in a separate cohort of hospitalized COVID-19 patients. Investigation of the role of secretor status in relation to disease severity revealed that COVID-19 incidence in group A non-secretors was much lower than would be expected if the absence of active FUT2 had no impact on disease, within the hospitalized patient context. Moreover, this effect was specific to blood group A and was not observed in patients with blood group O. 

Red cells were tested serologically for ABO, Rh, and Lewis using relevant DiaClon cards in accordance with the manufacturer's instructions (Bio-Rad).

Genomic DNA was isolated from whole blood samples using the Pure-Link Genomic DNA Mini kit according to the manufacturer's instructions (Invitrogen).

Genotyping of the FUT2 G428A polymorphism ABH antigen secretor status was determined by allele-specific PCR of the G428A polymorphism in the FUT2 gene. PCR products of 131-132 bp were obtained using modified versions of primers described by Moreno et al [16] . Detection of the wild-type allele used a G-specific forward primer 5′-CCGGCTACCCCTGCTCGTG-3′ and the common reverse primer 5′-CCGGCTCCCGTTCACCTG-3′. Detection of the null allele that prevents secretion used an A-specific forward primer 5′-ACCGGCTACCCCTGCTCGTA-3′ with the common reverse primer.

Samples with discrepant results for genotyping and Lewis serology underwent sequencing of the FUT2 and FUT3 coding regions using primers described by King et al 2019 [17] .

ABO genotype of the DISCOVER DNA samples was determined using three allelic discrimination assays to assess the polymorphisms at positions 261 (+/-G), 526 (C/G), and 703 (G/A) of the ABO gene.

The assay for position 526 was the TaqMan SNP genotyping assay C__27859399_10 (SNP ID rs7853989) (ThermoFisher Scientific). The other two assays used primers and TaqMan probes designed by Molecular Diagnostics, NHSBT. Sequences are available on request from the authors. All assays were run in 20µl volumes on a real-time PCR system, according to manufacturer's instructions (Applied Biosystems).

Statistical analysis were performed with the use of R (v4.0.0) [ 

A total of 471 adult patients had been admitted to North Bristol NHS Trust (UK) with a positive PCR result for SARS-CoV-2, and ABO blood group data were available for 44% (n = 209) of these. Retrospective analysis of these data revealed that among all the blood types, blood type A was the most common in COVID-19 patients, followed by O, B, and then type AB as the least common (Tables 1 and S1 [20] . The increased risk of hospitalization for blood group A for COVID-19 is significant and is accompanied by a significantly higher instance of respiratory failure on admission, requiring ventilation (p = 0.01525). However, there was no significant association with length of stay in hospital or patient death rate.

Hospitalized type A and O COVID-19 patients also had a similar age range (average +/-SD for A = 74.5 +/-16.9 and O = 72.6 +/-17.9).

Interestingly, while the distribution of ethnicities was near-identical between type A and type O individuals, we observed a striking gender distribution in this study (Tables 1 and 2) with 64% of males in the type A group compared to 43% with O type and conversely, more females with type O compared to A (56% vs. 35%) in this cohort. These observations match previous reports of male gender as a risk factor for COVID-19 [21] , but this variation is unexplained in the context of blood type. Importantly, we observe a trend between blood group A status and complications with cardiovascular disease (Tables 1, 2 , and S1). 

To further investigate the association of COVID-19 with blood group type, blood samples collected by the DISCOVER study were tested for ABO group and secretor status using DNA-based methodologies ( [22] . No initial correlation with Se genotype (SeSe versus Sese) and disease outcome was observed.

After additional blood group genotype analysis, this showed there were three deaths among only nine AA Se/Se or Se/se patients compared with two deaths from 53 AO Se/Se or Se/se patients ( we observed a lower than expected number of non-secretors in blood group A donors who had reported hospitalization (N = 55), but note that this analysis is based on a small sample size ( Table 6) . Importantly, across all convalescent donors sampled, we observed the anticipated number of non-secretors. However, in patients with blood type A, a higher-than-expected number of non-secretors was identified (25% vs.

20%, p = 0.01) ( Table 6) . Taken together, the DISCOVER study and convalescent plasma donor study results suggest that blood type A nonsecretors are not necessarily protected from SARS-CoV-2 infection but may experience less severe disease.

Studies carried out in hospitalized SARS-CoV-2 patients in China were the first to link blood group A with greater susceptibility to COVID-19 compared to blood group O [15] . Since then, multiple other studies carried out in other countries have supported an association between ABO type and SARS-CoV-2 susceptibility to infection and/or outcomes [24] [25] [26] [27] . The reasons for the association of severe COVID-19 with blood type A are unknown, but it has been suggested that this could be caused by O group patients having anti-A type antibodies [28] , that A type glycans could function as co-receptors for SARS-CoV-2 [29] or due to the known effects of blood groups on thrombosis risk due to von Willebrand factor (VWF) levels [30] . However, recently, the conclusion that ABO group influences COVID-19 severity has been questioned [31, 32] .

Here, we report a significant increased risk of hospitalization for blood group A COVID19 patients compared to patients with blood group O. This was accompanied by a significantly higher instance where no bias to blood group A over group O was observed [32] . We propose that the apparently conflicting results between studies to date can be explained by the nature of the patient population studied, because many studies focus on patient populations ill enough to need hospital admission. Such individuals are mostly elderly and more likely to have comorbidities.

The association of blood group A with cardiac disease is well documented and is linked to VWF (reviewed by Ward et al [33] ). Our data are the first to specifically link the severity of disease in COVID-19

patients to homozygous group A individuals who are also secretors.

ABO antigens are present on VWF, and group O VWF has been shown to have a shorter half-life in plasma than non-group O VWF [34] and corresponds with the observation that levels of VWF in plasma are known to be highest in homozygous group A individuals and homozygous Se individuals [35] . VWF forms high molecular multimers with increasing levels of multimerization leading to increased VWF adhesion to collagen and VWF induced platelet aggregation [36] . Plasma levels of VWF multimers are regulated by proteolytic cleavage by ADAMTS13 [37] with N-glycosylation of VWF, particularly at position 1574 near the site of cleavage by ADAMTS13, providing some protection against proteolysis [38] . It follows that more extensive glycosylation of VWF found in group A secretors but lacking in group O secretors would also result in higher circulating levels of high molecular weight VWF multimers in Group A. In addition, it has been observed that ABO genotype is a major determinant of ABO expression on platelets with homozygous A giving the highest expression [39] ; ABO expression on platelets determines how they adhere to VWF captured by exposed collagen in the endothelium [40] , with non-group O platelets adhering more strongly than group O. This leads to increased and more stable thrombus production in non-group O individuals. Therefore, group A and homozygous Se individuals have higher plasma levels of VWF, less proteolytic cleavage of high molecular weight multimeric VWF, and group A platelets adhere more strongly to VWF. The cumulative effect would predispose homozygous Se Group A patients to cardiac problems and thrombosis during infections with SARS-CoV-2. The mechanism whereby infection with SARS-CoV-2 influences this predisposition is currently unknown, but COVID-19 has been reported to be associated with inducing a hypercoagulable state [41] . It is known that VWF protein levels associated with pulmonary vascular endothelial cells are linked to ABO determinants [42] . We speculate that binding of SARS-CoV-2 virus to its receptor ACE2 in the lungs may activate TA B L E 5 Retrospective analysis of patients admitted to North Bristol NHS Trust (UK) and enrolled onto the DISCOVER study, that were genotyped for ABO blood group and secretor status. 

The authors declare no competing financial interests.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Disease and evolution

The histological distribution of blood group substances A and B in man

Sequence and expression of a candidate for the human Secretor blood group alpha(1,2)fucosyltransferase gene (FUT2)

Molecular cloning of a human genomic region containing the H blood group alpha(1,2)fucosyltransferase gene and two H locus-related DNA restriction fragments. Isolation of a candidate for the human Secretor blood group locus

Correlation between Lewis blood group and secretor character in man

Tissue distribution of histo-blood group antigens

The relationship between blood groups and disease

Infection's sweet tooth: how glycans mediate infection and disease susceptibility

Epidemiologic association between FUT2 secretor status and severe rotavirus gastroenteritis in children in the United States

Histo-blood group antigens in children with symptomatic rotavirus infection

Genetic susceptibility to human norovirus infection: an update

FUT2 secretor genotype and susceptibility to infections and chronic conditions in the ALSPAC cohort

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Relationship between the ABO Blood Group and the COVID-19 susceptibility

Analysis of the FUT2 gene and secretor status in patients with oral lesions

Fucosyltransferase gene polymorphisms and Lewisb-negative status are frequent in Swedish newborns, with implications for infectious disease susceptibility and personalized medicine

R: a language and environment for statistical computing. R Foundation for Statistical Computing

A toolbox for public health and epidemiology

Blood types

COVID-19 gender susceptibility and outcomes: a systematic review

The distribution of the human blood groups, and other polymorphisms

Convalescent plasma for COVID-19: Back to the future

The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19

Reduced prevalence of SARS-CoV-2 infection in ABO blood group O

Blood type and outcomes in patients with COVID-19

ABO phenotype and death in critically ill patients with COVID-19

Blood group ABO polymorphism inhibits SARS-CoV-2 infection and affects COVID-19 progression

Harnessing the natural antiglycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2

More on 'Association between ABO blood groups and risk of SARS-CoV-2 pneumonia'

COVID-19 and ABO blood groups

ABO blood groups are not associated with risk of acquiring the SARS-CoV-2 infection in young adults

The relationship between ABO blood group, von Willebrand factor and primary hemostasis

A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor

Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level

Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII

Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family

N-linked glycosylation of VWF modulates its interaction with ADAMTS13

Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor

Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function

Coagulation abnormalities and thrombosis in patients with COVID-19

SUPPORTING INFORMATION Additional supporting information may be found online in the Supporting Information section at the end of the article. How to cite this article